OnKure Therapeutics, Inc.: 5%+ holders

As of November 6, 2026, 8 holders' latest Schedule 13D or 13G filings report owning 5% or more of OnKure Therapeutics, Inc. The largest reported stake is AI Biotechnology LLC's, at 19.99%. 21 filings are on record since August 14, 2025 (Schedule 13D, April 7, 2026).

StepStone Group LP also filed stake reports on 2 other companies ↓

Sell to companies like OnKure Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-10-07 · Reporting person: Coastlands Capital LP · Sole voting: 0 · Shared voting: 2,700,000 · Sole dispositive: 0 · Shared dispositive: 2,700,000 · SCHEDULE 13G, 2026-10-07
• Filing 2026-08-14 · Reporting person: Biotechnology Value Fund L P · Sole voting: 0 · Shared voting: 1,671,617 · Sole dispositive: 0 · Shared dispositive: 1,671,617 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-14 · Reporting person: ADAR1 Capital Management, LLC · Sole voting: 0 · Shared voting: 2,238,684 · Sole dispositive: 0 · Shared dispositive: 2,238,684 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-14 · Reporting person: Trails Edge Capital Partners, LP · Sole voting: 1,438,456 · Shared voting: 0 · Sole dispositive: 1,438,456 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-10 · Reporting person: Prosight Management, LP · Sole voting: 0 · Shared voting: 978,992 · Sole dispositive: 0 · Shared dispositive: 978,992 · SCHEDULE 13G/A, 2026-08-10

OnKure Therapeutics, Inc. has 21 Schedule 13D or 13G filings on record since 2025-08-14. 8 holders' latest filing reports 5% or more of class a common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind OnKure Therapeutics, Inc. and the warning signs.

See OnKure Therapeutics, Inc.'s free Snapshot Watch OnKure Therapeutics, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on OnKure Therapeutics, Inc. and the records around it.

OnKure Therapeutics, Inc. elsewhere on the record

• Leadership changes Aug 2026
• Who owns it

Companies that share a holder

• StepStone Group LP also filed stake reports on 2 other companies: StepStone Private Equity Strategies Fund (May 2026)
• AI Biotechnology LLC also filed stake reports on 3 other companies: Latigo Biotherapeutics, Inc. (Nov 2026), Yarrow Bioscience, Inc. (Jul 2026), Zura Bio Limited (Mar 2026)
• Cantor Fitzgerald Securities also filed stake reports on 3 other companies: Satellogic Inc. (Mar 2026), M3-Brigade Acquisition V Corp. (Mar 2026), Sono Group N.V. (Feb 2026)

Want the whole picture on OnKure Therapeutics, Inc.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on OnKure Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on OnKure Therapeutics, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   23 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies OnKure Therapeutics, Inc. by CUSIP 68277Q105 and gives its principal executive office as 6707 Winchester Circle, #400, Boulder, CO 80301 (SCHEDULE 13G, 2026-10-07).

What the percentages are based on

The following percentages are based on 40,395,480 Shares outstanding as of May 4, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 5, 2026.Bvf Partners L P, SCHEDULE 13G/A, 2026-08-14

Purpose of Transaction (Item 4)

AI Biotechnology LLC

The information set forth in Item 3 and Item 6 hereof is hereby incorporated herein by reference. The Reporting Persons who hold securities of the Issuer directly acquired those securities as an investment in the regular course of their businesses. The Reporting Persons may engage in discussions with management, the Issuer's board of directors, other stockholders of the Issuer and other relevant parties concerning the business, operations, board composition, management, strategy and future plans of the Issuer. Dr. Liam Ratcliffe, who is currently employed by Access Industries, Inc., an affiliate of AIB, as its Head of Biotechnology, serves on the board of directors of the Issuer (in connection with the board designation right set forth in the Securities Purchase Agreement, as described in Item 3). The Reporting Persons intend to re-examine their investment from time to time and, depending on prevailing market conditions, other investment opportunities, liquidity requirements or other investment considerations the Reporting Persons deem material, the Reporting Persons may from time to time acquire additional securities of the Issuer in the open market, block trades, negotiated transactions, or otherwise and may also dispose of all or a portion of the Issuer's securities, in open market or privately negotiated transactions, and/or enter into derivative transactions with institutional counterparties with respect to the Issuer's securities, in each case, subject to limitations …The first part of Item 4 of the SCHEDULE 13D filed 2026-04-07; the filing has the rest

Timeline

Swipe the table sideways to see every column.

Questions about who owns OnKure Therapeutics, Inc.

Who owns OnKure Therapeutics, Inc.?

On this page, 8 holders' latest ownership filings report 5% or more of OnKure Therapeutics, Inc.: AI Biotechnology LLC (19.99%, Schedule 13D, filed 2026-04-07), RA Capital Management, L.P. (9.9%, Schedule 13G, filed 2026-04-07), Anders Hove (9.5%, Schedule 13G, filed 2026-04-01), Bvf Partners L P (8%, Schedule 13G/A, filed 2026-08-14) and Coastlands Capital LP (6.67%, Schedule 13G, filed 2026-10-07); 3 more are listed above.

Who are the largest shareholders of OnKure Therapeutics, Inc.?

By the share each holder's latest filing reports, the largest holders of OnKure Therapeutics, Inc. on this page are AI Biotechnology LLC (19.99%), RA Capital Management, L.P. (9.9%) and Anders Hove (9.5%).

When did AI Biotechnology LLC buy into OnKure Therapeutics, Inc.?

The filings give report dates, not purchase dates. The earliest filing from AI Biotechnology LLC on this page is the Schedule 13D, filed 2026-04-07, reporting 19.99%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 21 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for OnKure Therapeutics, Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for OnKure Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when OnKure Therapeutics, Inc. is mentioned again
• Find former OnKure Therapeutics, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes